St. Jude Medical ( STJ) surged 7% early Monday after guiding higher on fourth-quarter sales.

The medical-device maker said it expects to make 42 cents a share, after a 3-cent research-and-development tax credit. That's in line with the 39-cent Thomson Financial analysts' estimate.

But the company said sales will come in at $864 million, above the $843 million target.

Implantable cardioverter defibrillators, devices used to shock twitching hearts back to normal rhythms, brought in about $289 million. In its third-quarter earnings report, the company said it expected $265 million to $295 million in fourth-quarter sales of the devices.

Sales of atrial fibrillation products, which treat a certain type of abnormal heart rhythm, were approximately $91 million, beating the company's own estimates of between $80 million to $85 million. This represents a more than 26% increase over the fourth quarter of 2005.

Neuromodulation product sales were $50 million, compared with the company's previous estimates of $42 million to $47 million. Cardiology and cardiac surgery product sales also exceeded expectations, at $117 million and $71 million respectively. The company was expecting cardiology sales of $105 million to $115 million and cardiac surgery sales of $65 million to $70 million. Additionally, pacemaker sales for the fourth quarter were $246 million, up 6% over the fourth quarter of 2005.

Shares were rising $2.37 to $37.37.

If you liked this article you might like

Nationwide Egg Recall Expanded

10 Toy Fads That Have Faded

Boomers Feel Recession Burden, Blame

KFC Franchisees Want 'Fried' to Be the Focus

Heavy Weights: More Expensive, Less Effective